Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$4.8MCash on Hand
6.8mo Cash Runway
Follow SLXN by emailGet an email when SLXN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SLXN, unsubscribe in one click. Privacy
📣 What SLXN Says Is Next
coming months · “Additional Israeli oncology centers, alongside leading academic medical institutions in Germany approved under the European Union Clinical Trials Regulation (EU CTR) framework by the Federal Institute for Drugs and Medical Devices (BfArM), are progressing through site activation and are expected to join the Phase 2/3 program in the coming months.”
Company press release, Sep 30, 2026 · SEC filing
early 2027 · “SIL 204 Phase 2 / 3 in locally advanced pancreatic cancer received regulatory approval in Israel and Germany, initiated clinical trial July 2026 ; pre - IND meeting with FDA expected early 2027”
Company press release, Aug 10, 2026 · SEC filing
early 2027 · “The Company also plans to submit a Phase 2/3 clinical trial application in Germany by the end of this current quarter, with additional regulatory filings across the European Union planned in early 2027.”
Company press release, Mar 24, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Earnings Q3 2026 net loss was about $2.5 million, down from $3.3 million a year earlier. Cash and equivalents were $4.8 million and shareholders' equity $3.0 million at September 30, 2026. The first patient was dosed in the Phase 2/3 SIL204 pancreatic cancer trial, and a 1-for-24 reverse split took effect November 10, 2026. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Restructuring Silexion Therapeutics completed a 1-for-24 reverse share split effective after the close on November 10, 2026, with trading on a split-adjusted basis from November 11 under the existing ticker SLXN. Warrant terms were adjusted, with the exercise price raised to $372,600.00 per post-split share. Form 8-K · SEC filing
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 9, 2026 ·
Listing Silexion Therapeutics announced a 1-for-24 reverse share split of its ordinary shares, effective after market close on November 10, 2026, with trading on a split-adjusted basis beginning November 11, 2026, under the ticker SLXN. Form 8-K · SEC filing · Press release
Oct 28, 2026 ·
Financing Registers resale of up to 8,813,531 ordinary shares by selling shareholders, mainly warrant shares from a September 2026 warrant inducement at $0.2603 per share, plus shares issued on note conversion and for services. Company gets no resale proceeds. Form S-3 · SEC filing
Oct 26, 2026 ·
Shareholder vote Shareholders approved increasing authorized share capital from 15,900,000 to 515,900,000 ordinary shares and a reverse split of 1-for-24 at a reconvened meeting on Oct 26, 2026, with 95.4% and 97.7% of votes cast in favor. Form 8-K · SEC filing
Oct 5, 2026 ·
Shareholder vote Silexion asks shareholders to approve a 500,000,000 share increase in authorized capital, to 515,900,000 shares, and a reverse split at a ratio of 1-for-15 to 1-for-25 chosen by the board. Nasdaq shareholders' equity and $1.00 bid price compliance are cited as reasons. The meeting is October 19, 2026. Form DEF 14A · SEC filing
Sep 30, 2026 ·
Clinical trial Silexion Therapeutics announced the first patient dosed in its global Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, administered at Tel Aviv Sourasky Medical Center. The trial plans an initial safety cohort of about 18 patients, then a randomized cohort of about 166. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
SLXN holds $4.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.1M/quarter from operations,
an estimated runway of 6.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:70 · High
Cash runway 7 months +30
ATM program on file since Sep 2025 +15
Shelf registration (S-3, Jun 2026) +10
Going-concern doubt in the latest 10-Q +15Under these circumstances, in accordance with the requirements of Accounting Standards Codification (“ASC”) 205-40, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern, as management believes its current funds will be sufficient to fund its operations for…10-Q, Nov 2026
Share count 649,528 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full SLXN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SLXN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.